Finding a pan tumour clinical trial

• FORE
• • A Phase 2 Master Protocol to assess the efficacy and safety of FORE8394, an inhibitor of BRAF class 1 and class 2 alterations, in participants with cancer harbouring BRAF alterations
  • Patients with advanced, unresectable tumours with BRAF abnormalities could be suitable for this trial’s cohorts
• STRIKE
  • A multicentre randomised open-label phase III study of stereotactic radiosurgery, in addition to standard systemic therapy for patients with metastatic melanoma or newly diagnosed metastatic NSCLC and asymptomatic or oligo-symptomatic brain metastases
  • Patients with newly diagnosed brain metastases from either metastatic melanoma [with/without BRAF mutation], or newly diagnosed, treatment naïve metastatic MSLC [with/without driver alteration]
• MITRE
  • A study to evaluate the microbiome as a biomarker of efficacy and toxicity in cancer patients receiving immune checkpoint inhibitor therapy
  • A study which could be suitable for patients due to commence treatment with a systemic therapy, including PDL1 and anti CTLA-4 antibodies in the following disease areas; Melanomia, Renal, Advanced NSCLC
  • Consented patient will be asked to provide clinical information and biological samples
• LION
  • A study to evaluate the microbiome as a biomarker of efficacy and toxicity in cancer patients receiving immune checkpoint inhibitor therapy
  • A study which could be suitable for patients diagnosed with TNBC, RCC, NSCLC, assessing the suitability of celecoxib in combination to the standard of care treatment for each disease area.

• BCGC [Set Up]
  • A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) study
• PAN TUMOUR 1 [Feasibility]
  • A Phase II, multicenter, multi-cohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours
  • The trial could be suitable for patients with HER2 mutated/HER2 overexpressed or amplified, Urothelial, Biliary tract, Uterine, Cervical, NSCLC, Breast, Gastroesophageal and Tumour-Agnostic cancer
• MK1084-014 [Feasibility]
  • A Phase 2, Open-Label, Multicenter, Tumor-agnostic Basket Study of MK‑1084 as Monotherapy and in Combination with Cetuximab in Participants with KRAS G12C Mutant, Advanced Solid Tumors (KANDLELIT-014)
  • The trial could be suitable for patients diagnosed with NSCLC, PDAC, EC, BTC cancers who have KRAS G12C mutation. The trial will also consider other disease areas. Please get in touch with the research team for further information
• ELE 4008 [Feasibility]
  • A Phase 2, Open-Label, Single-Arm Study of Lirafugratinib in Patients with Previously Treated, Unresectable, Locally Advanced or Metastatic Solid Tumors (Excluding Cholangiocarcinoma) With FGFR2 Fusion or Rearrangement
  • The trial could be suitable for patients which cervical, endometrial, ovarian, breast, colorectal, gastroesophageal, lung, pancreatic, prostate, urothelial and other disease areas
• MK2010 [Feasibility]
  • A Phase 2, Randomized, Open-label Clinical Study to Evaluate the Safety and Preliminary Efficacy of MK-2010
  • The study could be suitable for patients with NSLC, Gastric, HNSCC, CRF, RCC, BTC, ESCC, HCC, Melanoma and Ovarian cancers. Please get in touch with the research team for further information on inclusion/exclusion

For further information on inclusion/exclusion and our portfolio of studies, please get in touch with the pan tumour research team by email at the-christie.pantumour.latephase@nhs.net